Ruxolitinib is a Janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme.
JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.
Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis.
Herpes zoster (shingles) and opportunistic infections.
Metabolic side effects have included weight gain.
Laboratory abnormalities have included alanine transaminase (ALT) abnormalities, aspartate transaminase (AST) abnormalities and elevates cholesterol level
The U.S. Food and Drug Administration (FDA) granted marketing approval for Jakafi® (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Ruxolitinib demonstrated efficacy in controlling hematocrit, as well as for improving the spleen, polycythemia vera-related systemic symptoms and overall blood cell count. A greater proportion of patients on the ruxolitinib treatment arm achieved complete hematologic remission, defined as achieving hematocrit control, and lowering platelet and white blood cell counts.
Article By - Chirag Navadia, Founder of MedRx, www.medrx-education.com Reference: www.jakafi.com